[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"myomectomy\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:myomectomy":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,45,71,100],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":4},"100641538","aerobic-versus-resistance-exercises-on-disability-after-abdominal-myomectomy-100641538",false,"NCT07661147","Aerobic Versus Resistance Exercises on Disability After Abdominal Myomectomy","RE","Inclusion Criteria:\n\n* All patients are conscious and ambulant.\n* Their ages ranged from 30-60 years old.\n* All patients will be under post abdominal myomectomy (6-12 months) management program.\n* All patients will not suffer from any complication post abdominal myomectomy, except weakness of abdominal muscles.\n* All patients will receive and agreed to sign the informed consent form.\n\nExclusion Criteria:\n\n* The patient who has cardiovascular diseases, or uncontrolled hypertension.\n* The patient who has cardiac pacemakers or other implanted electronic devices.\n* Uncooperative patients.\n* Patients who have cardiopulmonary diseases.\n* Patients who have psychic disorders.\n* Patients with neuromuscular diseases.\n* Pregnant female.\n* Patients who have any endocrine, metabolic, renal or hepatic diseases. Patients who have an open wound at or near the treatment site.","FEMALE","30 Years","60 Years",{"count":20,"type":21},60,"ESTIMATED","INTERVENTIONAL",[24],"NA","This study will be conducted to compare aerobic and resistance exercises on disability after abdominal myomectomy.",[27],"Myomectomy",[29,30,31,32],"aerobic exercises","resistance exercises","disability","abdominal myomectomy","NOT_YET_RECRUITING","2026-06-16",{"date":36,"type":37},"2026-06-22","ACTUAL",{"date":39,"type":21},"2026-06-25",{"date":41,"type":21},"2026-10-30",{"name":43,"class":44},"Cairo University","OTHER",{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":4,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":16,"minAge":52,"maxAge":53,"enrollmentInfo":54,"targetDuration":4,"studyType":22,"phases":56,"briefSummary":57,"conditions":58,"keywords":4,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":70},"100634241","lidocaine-for-less-postoperative-shoulder-pain-alleviation-100634241","NCT07537127","Lidocaine for LESS Postoperative Shoulder Pain Alleviation","Subdiaphragmatic Infiltration of Diluted Lidocaine During Single-incision Laparoscopic Surgery for Postoperative Shoulder Pain Alleviation","Inclusion Criteria:\n\n* Age: Female patients aged 18-65 years;\n* Clear preoperative diagnosis, suitable for single-port laparoscopic surgery, and American Society of Anesthesiologists (ASA) physical status classification I-II;\n* Patients or their family members can understand the study protocol, are willing to participate in the study, and provide written informed consent.\n\nExclusion Criteria:\n\n* Allergy to lidocaine or amide-type local anesthetics;\n* Severe medical comorbidities;\n* Long-term preoperative use of opioid drugs or sedatives;\n* Pregnant or lactating women;\n* Conversion to laparotomy or addition of surgical ports during surgery.","18 Years","65 Years",{"count":55,"type":21},100,[24],"Objective: To evaluate the efficacy of subdiaphragmatic spray of 0.08% lidocaine in relieving postoperative acute pain and psychological status of patients undergoing single-port laparoscopic surgery for benign gynecological diseases, and to provide evidence-based basis for optimizing postoperative analgesic strategies.\n\nMethods: A single-center, prospective randomized controlled study was conducted. A total of 100 patients scheduled for elective single-port laparoscopic surgery due to uterine fibroids, ovarian cysts, or other benign gynecological conditions were selected from the General Gynecology Center of Peking Union Medical College Hospital. They were divided into the experimental group (n=50) and the control group (n=50) using a random number table. The experimental group received 50 ml of 0.08% lidocaine solution sprayed on the bilateral subdiaphragmatic regions at the start of surgery, while the control group underwent standard ERAS without any pharmaceutical intervention in the subdiaphragmatic area. The primary endpoint was the Numerical Rating Scale (NRS) score for resting pain at 6 hours postoperatively. The secondary endpoints included NRS scores at 1, 2, 12, and 24 hours postoperatively, total consumption of analgesics within 48 hours after surgery, incidence of adverse reactions, patient satisfaction, and scores of psychological and sleep scales (Distress Thermometer, GAD-7, etc.) at 30 days postoperatively. SPSS 25.0 software was used for data analysis. Quantitative data were analyzed by t-test or Mann-Whitney U test, and qualitative data were analyzed by χ² test or Fisher's exact test. Repeated measurement data were analyzed by repeated measures analysis of variance.\n\nResults: After the completion of the study, differences in NRS scores, analgesic consumption, psychological status and other indicators between the two groups will be compared.\n\nConclusion: The results of this study will clarify the clinical value of intraoperative diaphragmatic infiltration with low-concentration lidocaine in postoperative analgesia after single-port laparoscopic gynecological surgery, and provide references for postoperative pain management and psychological intervention.",[59,27],"Cystectomy","RECRUITING","2026-04-12",{"date":63,"type":37},"2026-04-17",{"date":65,"type":37},"2025-12-15",{"date":67,"type":21},"2026-08-14",{"name":69,"class":44},"Peking Union Medical College Hospital",1,{"id":72,"slug":73,"hasResults":11,"nctId":74,"briefTitle":75,"officialTitle":76,"acronym":4,"eligibilityCriteria":77,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":78,"targetDuration":4,"studyType":22,"phases":79,"briefSummary":80,"conditions":81,"keywords":84,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":91,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":99},"100620064","bilateral-uterine-artery-occlusion-during-laparoscopic-myomectomy-100620064","NCT07352761","Bilateral Uterine Artery Occlusion During Laparoscopic Myomectomy","Comparing Different Techniques of Bilateral Uterine Artery Occlusion During Laparoscopic Myomectomy: A Randomized Controlled Trial","Inclusion Criteria:\n\n* women with uterine fibroids and complaining of either abnormal uterine bleeding, infertility, urinary or rectosigmoid pressure manifestations.\n* Fibroid size from 3 - 10 cm in diameter and with\n* a maximum number of 3 fibroids.\n\nExclusion Criteria:\n\n* contraindication to pneumoperitoneum and laparoscopy,\n* patients with BMI \\> 30 kg\u002Fm2,\n* history of midline abdominal incisions,\n* women with history of prior ovarian surgery,\n* women with history of hormonal treatment for the last 3 months before surgery,\n* women who are not good candidate for myomectomy and who would benefit more from hysterectomy such as, women with multiple ≥ 4 leiomyomata, associated adenomyosis, recurrent fibroids after myomectomy.\n* suspected endometrial malignancy or suspected leiomyosarcoma features on ultrasound and\u002For MRI.\n* Submucous fibroids who will undergo hysteroscopic myomectomy beside the laparoscopic surgery.",{"count":20,"type":21},[24],"The current study is a multiple-arm, single blinded, and controlled randomized trial. It will be conducted in two gynecological endoscopy centers: • ElShatby University Hospital, a tertiary level hospital in Alexandria, Egypt. • Al-Madina Women Hospital, A specialized hospital of Obstetrics and Gynecology, Alexandria, Egypt. Patient selection: women with uterine leiomyomata and planning for laparoscopic myomectomy will be assessed for eligibility then will be enrolled in the trial according to the following inclusion and exclusion criteria, after providing a written informed consent of participation. Outcome variables of the study: The primary outcome is intraoperative blood loss and the change in postoperative hemoglobin. The secondary outcomes of this study are the operative time of performing uterine arteries occlusion and the postoperative ovarian reserve.",[82,27,83],"Uterine Fibroids (Leiomyoma)","Myomectomy; Surgical Blood Loss",[85,86,87,88,89],"Fibroids","Laparoscopic myomectomy","Blood loss","Uterine artery occlusion","Ovarian reserve","2026-01-13",{"date":92,"type":37},"2026-01-20",{"date":94,"type":37},"2025-05-01",{"date":96,"type":21},"2026-02-28",{"name":98,"class":44},"Alexandria University",2,{"id":101,"slug":102,"hasResults":11,"nctId":103,"briefTitle":104,"officialTitle":104,"acronym":105,"eligibilityCriteria":106,"healthyVolunteers":11,"sex":16,"minAge":52,"maxAge":4,"enrollmentInfo":107,"targetDuration":4,"studyType":22,"phases":109,"briefSummary":110,"conditions":111,"keywords":115,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":120,"lastUpdatePostDateStruct":121,"startDateStruct":123,"completionDateStruct":125,"leadSponsor":127,"locationsCount":70},"100592080","assessment-of-tubal-occlusion-during-minimally-invasive-myomectomy-100592080","NCT06988774","Assessment of Tubal Occlusion During Minimally Invasive Myomectomy","ATOM","Inclusion Criteria:\n\n* Patients undergoing minimally invasive laparoscopic or robotic-assisted uterine-preserving gynecologic surgery for removal of uterine fibroids (myomectomy) by a minimally invasive gynecologic surgeon at MedStar.\n\nExclusion Criteria:\n\n* Patients with both fallopian tubes absent\n* Patients in whom it is not possible to place a uterine manipulator or catheter\n* Patient with known tubal disease or occlusion, or patients who have undergone prior tubal surgery\n* Patients with allergy to methylene blue dye or G6PD deficiency\n* Patients with positive pregnancy test on day of surgery",{"count":108,"type":21},50,[24],"This study uses a procedure called chromopertubation to look at how fibroids and fibroid surgery affect the fallopian tubes. Specifically, this study will test if the fallopian tubes are occluded or patent (open) before and after surgically removing fibroids.\n\nChromopertubation is a commonly performed and well-established procedure that is done during laparoscopic surgery to determine if the fallopian tubes are open or blocked. It includes inserting a dilute solution of saline with a small amount of medical-grade blue dye (called methylene blue) into the uterine cavity to see if it spills out of the fallopian tubes. Chromopertubation is considered a safe procedure - the main risk is an allergic reaction to the dye, which is very rare. The minimum amount of methylene blue dye will be used to further reduce risks of a reaction.\n\nOpen fallopian tubes are necessary to become pregnant without the use of IVF. While it is known that some conditions can affect the functioning of the fallopian tubes, there is a lack of research about how fibroids affect the tubes. It is also not known how much about how the process of removing fibroids may affect the fallopian tubes. The investigators hypothesize that tubal occlusion will be observed in patients with fibroids and that the frequency of tubal occlusion will change after myomectomy compared to pre-myomectomy.\n\nThis study will be conducted entirely during planned surgery for laparoscopic myomectomy. Chromopertubation will be performed at the beginning and again at the end of the surgery. This is expected to take less than 10 minutes in total. The results of the chromopertubation as well as background medical information will be recorded and the characteristics of the fibroids (size, number, and location) will be compared to the presence or abscence of tubal occlusion as determined by chromopertubation.",[112,113,27,114],"Fallopian Tube Patency Tests","Fibroid\u002FMyoma (Uterus\u002FCervix)","Fallopian Tube Disease",[116,117,118,119],"chromopertubation","myomectomy","uterine fibroids","fallopian tube disease","2025-06-25",{"date":122,"type":37},"2025-06-29",{"date":124,"type":37},"2025-06-02",{"date":126,"type":21},"2026-04-30",{"name":128,"class":44},"Medstar Health Research Institute"]